All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Hun LeeDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Targeting ROR-1 with zilovertamab in MCL and CLL
Lee provides a summary of the latest safety and efficacy data from a phase I/II study of zilovertamab + ibrutinib in relapsed/refractory CLL and MCL, outlining the encouraging progression-free survival rates seen even in high-risk patients with TP53 alterations. Lee then discusses plans for further study of the apparent synergy between zilovertamab and ibrutinib and a phase III study of zilovertamab + ibrutinib versus ibrutinib + placebo in R/R MCL to validate these findings
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?